Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
Crossref DOI link: https://doi.org/10.1007/s10549-014-3047-y
Published Online: 2014-07-14
Published Print: 2014-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Diaby, Vakaramoko
Adunlin, Georges
Ali, Askal Ayalew
Tawk, Rima
Text and Data Mining valid from 2014-07-14